Skip to main content

Behçet’s Disease: Visual Acuity after 5 Years in Patients with Alpha-Interferon Treatment

  • Chapter
Adamantiades-Behçet’s Disease

Conclusion

Compared to conventional immunosuppressants, IFN-α2a seems to be much more effective to prevent a loss or decrease of visual acuity over a long period of time in patients with severe ocular BD.

As 15 eyes is only a small case series, further evaluation is needed. We expect that in approximately 12 months 30 eyes will have reached the 5-year follow-up mark, so more data will soon then be available.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mishima, S., Masuda, K., Izawa, Y., et al., 1979, Behçet’s disease in Japan: ophthalmologic aspects. Tr. Am. Ophth. Soc. LXXVII: 225–279.

    Google Scholar 

  2. BenEzra, D., and Cohen, E., 1986, Treatment and visual prognosis in Behçet’s disease. Br. J. Ophthalmol. 70: 589–592.

    CAS  PubMed  Google Scholar 

  3. Cochereau-Massin, I., Wechsler, B., Le Hoang, P., et al., 1992, Pronostic oculaire de la maladie de Behçet. J. Fr. Ophthalmol. 15: 343–347.

    CAS  Google Scholar 

  4. Whitcup, S.M., Salvo, E.C., and Nussenblatt, R.B., 1994, Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet’s disease. Am. J. Ophthalmol. 118: 39–45.

    CAS  PubMed  Google Scholar 

  5. Zierhut, M., Saal, J., Pleyer, U., et al., 1995, Behçet’s disease: epidemiology and eye manifestations in German and Mediterranian patients. Ger. J. Ophthalmol. 4: 246–251.

    CAS  PubMed  Google Scholar 

  6. Kötter, I., Eckstein, A.K., Stübiger, N., et al., 1998, Treatment of ocular symptoms of Behçet’s disease with interferon α2a a pilot study. Br. J. Ophthalmol. 82: 488–494.

    PubMed  Google Scholar 

  7. Stübiger, N., Kötter, I., Deuter, C., et al., 2001, Behçet’s disease: uveitis-therapy with interferon α2a-prospective clinical study in 33 patients. Klin. Monatsbl. Augenheilkd. 218: 768–773.

    PubMed  Google Scholar 

  8. Kötter, I., Zierhut, M., Eckstein, A.K., et al., 2003, Human recombinant interferon-α2a for the treatment of Behçet’s disease with sight threatening posterior or panuveitis. Br. J. Ophthalmol., in press.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Kluwer Academic Publishers

About this chapter

Cite this chapter

Deuter, C.M., Kötter, I., Günaydin, I., Zierhut, M., Stübiger, N. (2004). Behçet’s Disease: Visual Acuity after 5 Years in Patients with Alpha-Interferon Treatment. In: Zouboulis, C.C. (eds) Adamantiades-Behçet’s Disease. Advances in Experimental Medicine and Biology, vol 528. Springer, Boston, MA. https://doi.org/10.1007/0-306-48382-3_105

Download citation

  • DOI: https://doi.org/10.1007/0-306-48382-3_105

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-306-47757-7

  • Online ISBN: 978-0-306-48382-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics